healthcare

A recent analysis reveals that Louisiana is the least healthy state in America.
Now is the time to reduce risk and more to safer ideas. Top-quality health care stocks may be the way to go for the rest of 2021 and in 2022, and these five Dividend Aristocrats make good sense now...
Health care is poised to benefit from a shift toward more defensive sectors. These five stocks have strong balance sheets, attractive dividend yields and improved cost structures. With even moderate...
While not suited for conservative income investors, these two top biotech stocks could have huge total return potential and offer investors with a touch more risk tolerance some very tempting entry...
Here's a quick look at six publicly traded companies developing ways to use psychedelics to treat mental health issues.
Pot grower Tilray is acquiring a majority position in U.S.-based cannabis retailer MedMen. Is this a portent of more consolidation in the industry?
These four big pharmaceutical stocks are rated Buy by top Wall Street firms and look like very good ideas for investors, especially now that the market is overbought and the slow seasonal market...
Senate Majority Leader Chuck Schumer is scheduled to announce legislation Wednesday that would decriminalize marijuana.
These four Jefferies stock picks in the health care space offer outstanding upside potential for investors long term and look like very solid ideas for the rest of 2021, especially with an overbought...
ETFMG on Thursday launched a new ETF that offers people a way to invest in cannabis companies that do at least half their business in the United States.
Canadian marijuana grower Tilray is getting a big boost Friday, a result of a stock upgrade and price target lift from analysts at Jefferies.
Frequency Therapeutics shares were absolutely crushed on Tuesday but saw a bit of a recovery early Wednesday.
Amazon on Wednesday announced an expansion of its health care service to all employers in Washington state. The announcement took a bite out of some competing health care stocks.
Rubius Therapeutics was one of Monday’s biggest winners after it announced initial data from its ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors.
Altimmune has announced additional preclinical data in regards to its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.